Enabling timely HIV postexposure prophylaxis access in sub-Saharan Africa
AIDS
.
2022 Aug 1;36(10):1473-1475.
doi: 10.1097/QAD.0000000000003258.
Authors
Andrew N Phillips
1
,
Euphemia Sibanda
2
,
Kenly Sikwese
3
,
Loveleen Bansi-Matharu
1
,
Valentina Cambiano
1
,
Alison Rodger
1
,
Jens Lundgren
4
,
Maryam Shahmanesh
5
,
Charlie Gilks
6
,
Catherine Godfrey
7
,
Peter Ehrenkranz
8
,
James R Hargreaves
9
,
Paul Revill
10
,
Frances Cowan
2
Affiliations
1
Institute for Global Health, UCL, London, UK.
2
Liverpool School of Tropical Medicine, UK, and Harare, Zimbabwe.
3
African Community Advisory Board (AfroCAB-HIV), Lusaka, Zambia.
4
Rigshospitalet, University of Copenhagen, Copenhagen, Denmark.
5
Africa Health Research Institute, KwaZulu-Natal, South Africa.
6
University of Queensland, Queensland, Australia.
7
Office of the Global AIDS Coordinator, Department of State, Washington, DC, USA.
8
Bill & Melinda Gates Foundation, Seattle, USA.
9
London School of Hygiene & Tropical Medicine, London.
10
Centre for Health Economics, University of York, UK.
PMID:
35876709
DOI:
10.1097/QAD.0000000000003258
No abstract available
MeSH terms
Africa South of the Sahara
Anti-HIV Agents* / therapeutic use
HIV Infections* / drug therapy
HIV Infections* / prevention & control
Humans
Substances
Anti-HIV Agents
Grants and funding
MR/S005307/1/MRC_/Medical Research Council/United Kingdom
MR/T042796/1/MRC_/Medical Research Council/United Kingdom